A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

Semaglutide improved time spent in glycemic range, time below rate and reduced body weight with low rates of hypoglycemia ...

A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

Incidence rates of composite of death, MI, stroke were lower, but not significantly so, for patients treated with semaglutide ...

This combination "provided weight loss in the highest range of efficacy observed with existing weight loss interventions," ...

The following is a summary of “Oral semaglutide for the treatment of obesity: a retrospective real-world study,” published in the May 2025 issue of Frontiers in Endocrinology by Krajnc et al. Clinical ...

Nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss, is a “very rare” side effect of treatment with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, ...

European regulators have confirmed that Novo Nordisk’s semaglutide increases the risk of a rare eye condition that can cause vision loss. The conclusion from the European Medicines Agency (EMA) ...

Packed with essential minerals and complete protein, amaranth is a versatile seed praised for boosting bone health and reducing cholesterol. Research highlights its anti-inflammatory properties and ...